** Drugmaker Axsome Therapeutics' AXSM.O shares rise 1.6% to $139.98 premarket
** AXSM says its drug, Symbravo, met the main goal in a late-stage trial to treat migraine headaches in patients who didn't respond well to other treatments
** Symbravo is a combination of two medicines, meloxicam and rizatriptan
** In the trial, Symbravo was found to be more effective than oral CGRP inhibitors in relieving migraine pain, with 47.9% of patients pain-free within 2 hours, compared with only 1% of patients who took oral CGRP inhibitors, the company says
** Symbravo is not recommended for people with heart problems, high blood pressure, or kidney disease, or for pregnant or breastfeeding women
** AXSM gained 6.3% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.